Citi Target on Amarin $13 PT On Upcoming First Qt. Earning Report. post.
The chance of the FDA approving this 2nd indication is high in our view. This would be the first approval for this class of drug in this setting which would provide a meaningful competitive advantage to the only other approved competitor from GSK. An approval in this broader indication could rekindle discussions with potential suitors for either partnership or potential takeout. We do believe that the full potential of this news could be mitigated by the upcoming 1Q:13 earnings. Target price $13.